Vertaling van "advanced 27 significantly ahead of sales " (Nederlands → Frans) :

Pharmaceuticals: USD 2.2 billion (+27%) Operating income advanced 27%, significantly ahead of sales, and still rose 16% when adjusted in both periods for currency changes (–6 percentage points) and exceptional items (+17 percentage points).
Pharmaceuticals: USD 2,2 milliards (+27%) Le résultat opérationnel a progressé de 27%, largement plus que le chiffre d’affaires, et de 16%, même après ajustement, dans les deux périodes de comparaison, des changes défavorables (-6 points de pourcentage) et des éléments exceptionnels (+17 points de pourcentage.

Core operating income advanced 23%, well ahead of sales and included four percentage points of positive currency impact.
Le résultat opérationnel «core» a progressé de 23%, soit bien plus vite que le chiffre d’affaires et a bénéficié d'un effet de change favorable.

Pharmaceuticals: USD 6.5 billion (+8%) Operating income grew 8%, well ahead of sales, and advanced at a faster 16% pace when adjusted in both periods for adverse currency movements (–10 percentage points) and exceptional items (+2 percentage points).
Pharmaceuticals: USD 6,5 milliards (+8%) Le résultat opérationnel a progressé de 8%, soit bien plus que le chiffre d’affaires, et même de 16%, après ajustement, dans les deux périodes de comparaison, des changes défavorables (-10 points de pourcentage) et des éléments exceptionnels (+2 points de pourcentage.

31-okt-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » meer
31-oct.-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » En savoir plus